Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Lewis Williams | M | 74 | 7 years | |
William Waddill | M | 67 | 8 years | |
Chirfi Guindo | M | 58 | 13 years | |
Bryan Giraudo | M | 49 | 6 years | |
Dalton Smart | M | 58 | 15 years | |
Carter J. King | M | 52 | 6 years | |
Richard DeLuca | M | 61 | 13 years | |
Ashok Bhandari | M | - | 7 years | |
Sanat Chattopadhyay | M | - | 15 years | |
Pamela Eisele | F | - | 15 years | |
Denise Williams | F | - | 15 years | |
Suneel Gupta | M | 66 | 5 years | |
Mohammad Masjedizadeh | M | - | 7 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Faheem Hasnain | M | 65 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 years |
Timothy Shannon | M | 65 |
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | 3 years |
Richard Clark | M | 77 | 6 years | |
Fred Hassan | M | 78 | 6 years | |
Carlos Eduardo Represas de Almeida | M | 78 | - | |
Samuel Saks | M | 69 | - | |
Julie Gerberding | M | 69 | - | |
Thomas O'Neil | M | 59 | 3 years | |
Bradford Goodwin | M | 69 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 years |
Michael Nally | M | 48 | 10 years | |
Thomas Robert Cech | M | 76 | - | |
Thomas Shenk | M | 77 | 11 years | |
Harry R. Jacobson | M | 76 | 3 years | |
Jean-Marie Canan | M | 68 | 5 years | |
Herbert Cross | M | 52 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | - |
Steven Goldstone | M | 78 | 6 years | |
Francis Sarena | M | 53 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 years |
Caroline Dorsa | F | 64 | 22 years | |
Julie Grant | F | 41 | 2 years | |
Sarah Noonberg | M | 56 | 6 years | |
William N. Kelley | M | 84 | - | |
Jeffrey Chodakewitz | M | 68 | 4 years | |
D. Gilliland | M | 69 | 4 years | |
Yan Li | F | 50 | 4 years | |
Graham Lumsden | M | 64 | 26 years | |
Gwen R. Carscadden | F | 62 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 years |
Rasappa Arumugham | M | 73 | 2 years | |
Mark Shearman | M | 62 | 3 years | |
Stephen Farrand | M | - | 6 years | |
Terrie Curran | F | 55 | 4 years | |
Timothy Murphy | M | 56 | 4 years | |
Sachin Jain | M | 43 | 2 years | |
Doron Ben-Ami | M | 72 | 5 years | |
Maarten van der Linden | M | 55 | 4 years | |
Lucio Tozzi | M | 60 | 4 years | |
Jens Renstrup | M | 59 | 8 years | |
Arnaub Chatterjee | M | - | 5 years | |
Jim Robinson | M | - | 5 years | |
Gerard Cunningham | M | - | 1 years | |
Carlos Lugo | M | - | 2 years | |
Mark Bach | M | 67 | 17 years | |
Yanni Souroutzidis | M | - | 2 years | |
Rafael Torgovicky | M | - | 2 years | |
Francesco Maria Lavino | M | 51 | 2 years | |
Sheldon Koenig | M | 58 | 6 years | |
Pernilla Sandwall | F | 61 | 8 years | |
Yao Lee | M | 54 | 3 years | |
Ernesto Aycardi | M | 61 | 11 years | |
Alexis Ji | M | - | 5 years | |
Hugo Wahnish | M | - | 18 years | |
Geralyn S. Ritter | F | - | 8 years | |
Lawrence D. Senour | M | 59 | - | |
Vijay Tammara | M | 64 | 6 years | |
Andrew Guggenhime | M | 55 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 years |
Bridgette Heller | F | 62 | 5 years | |
Dennis Erb | M | - | - | |
Richard S. Bowles | M | 72 | - | |
Evgeny Zaytsev | M | 56 |
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | - |
Jaisim Shah | M | 63 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 1 years |
Margaret McGlynn | F | 64 | 11 years | |
Gary Lyons | M | 73 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 years |
David Parkinson | M | 73 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 2 years |
Samuel O. Thier | M | 86 | 16 years | |
Pam Cheng | F | 53 | 5 years | |
Ted Llana | M | 60 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | - |
Stefan Oschmann | M | 66 | 20 years | |
James Christopher Scalet | M | 65 | 9 years | |
Raul E. Kohan | M | 71 | 1 years | |
Mark McCamish | M | 72 |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 1 years |
Anthony Rimac | M | 60 |
Aldea Pharmaceuticals, Inc.
Aldea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aldea Pharmaceuticals, Inc. develops novel enzyme activators to enhance the removal of toxic aldehydes. It targets Aldehyde metabolism dysfunction which is associated with a variety of diseases from acute alcohol toxicity to orphan indications such as Fanconi anemia. The company was founded by Daria Mochly-Rosen, Che-Hong Chen and Wenjin Yang in 2011 and is headquartered in Redwood City, CA. | 1 years |
Franklin Clyburn | M | 59 | 13 years | |
Peter Honig | M | 67 | 7 years | |
Glenn Williams | M | - | 10 years | |
Roger Pomerantz | M | 67 | 3 years | |
Bruno Strigini | M | 63 | 5 years | |
Eric Schadt | M | 59 | 8 years | |
Aaron Dent | M | - | 6 years | |
David A. Esposito | M | 55 | 13 years | |
Piotr Bobrowicz | M | - | - | |
David Monteith | M | 60 | 5 years | |
Daniel Bouthillier | M | - | 16 years | |
Christopher Garland | M | - | - | |
Cuong Viet Do | M | 58 | 3 years | |
Ami Knoefler | F | - |
Abbott Biotherapeutics Corp.
Abbott Biotherapeutics Corp. Pharmaceuticals: MajorHealth Technology Abbott Biotherapeutics Corp. engages in the identification and development of oncology therapeutics. The firm's products in development include Daclizumab, a monoclonal antibody in Phase IIb clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, a chimeric monoclonal antibody in Phase I clinical studies that inhibits the functional activity of a protein in activated endothelial cells. The company was founded in 2008 and is headquartered in Redwood City, CA. | 1 years |
Graeme Bell | M | 57 | 2 years | |
Michael Holston | M | 61 | 6 years | |
Milenko Cicmil | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard S. Shames
- Personal Network